coming soon…
1. CECOG Fireside Chat
Changing the ES-SCLC paradigm with immuno-oncology Combinations
Univ. Prof. Dr. Marko Jakopovic
Thoracic Oncology Unit
Department for Respiratory Diseases
University Hospital Centre Zagreb, Croatia
Univ Prof Dr. Wolfgang Köstler
Department of Medicine I,
Clinical Division of Oncology,
Medical University of Vienna, Austria
2. CECOG Fireside Chat
Patient needs in later lines of mBC (testing, efficacy of current treatment – what do we need)
Univ. Prof Dr. Alexandru Eniu
HÔPITAL RIVIERA-CHABLAIS, VAUD-VALAIS
Spécialiste FMH en oncologie médicale
Responsable Breast Unit, Switzerland
Univ Prof Dr. Rupert Bartsch
Department of Medicine I,
Clinical Division of Oncology,
Medical University of Vienna, Austria
3. CECOG Fireside Chat
Targeted treatment options to improve outcomes in EGFRm NSCLC
Univ. Prof. Dr Bojan Zaric
Institute for Pulmonary Diseases of Vojvodina
Faculty of Medicine
University of Novi Sad, Serbia
Univ. Prof Dr. Martin Filipits
Institute of Cancer Research
Department of Medicine I
Medical University of Vienna
4. CECOG Fireside Chat
How new treatments are impacting the work of Multidisciplinary Teams (MTD) (incl guidelines discussion)
Dr. Mila Petrova
MHAT Nadezhda
Sofia, Bulgaria
Univ. Prof. Dr. Christoph Zielinski
CECOG President
5. CECOG Fireside Chat
Clinical implementation of immuno-oncology therapy in unresectable stage III NSCLC
Univ. Prof.Dr. Tanja Cufer
University Clinic Golnik
Medical Faculty Ljubljana
Slovenia
Univ. Prof. Dr. Rafal Dziadziusko
Department of Oncology and Radiotherapy
Medical University of Gdansk
6. CECOG Fireside Chat
Zoom in for HER2+ space: Pharmacology & clinical (efficacy and safety) for trastuzumab deruxtecan Later lines of treatment
Univ. Prof. Dr. Evandro De Azambuja
Institut Jules Bordet
Belgium
Univ. Prof. Dr. Christoph Zielinski
CECOG President
Sponsored by Astra Zeneca
